Biotech Stocks Technical Report -- Achillion Pharma, Arrowhead Research, Sunesis Pharma, Array BioPharma, and Seattle Genetics
PR Newswire - Mon Dec 22, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Arrowhead Research Corporation (NASDAQ: ARWR), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Array BioPharma Inc. (NASDAQ: ARRY), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, December 19, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,804.80, up 0.15% and the NASDAQ Composite closed at 4,765.38, up 0.36%. The S&P 500 finished the session 0.46% higher at 2,070.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 816.95, up 0.41%, with the index advancing 9.33% in the previous three months. Register for your complimentary reports on these five stocks at:
SGEN: 31.10 (-0.14), ARWR: 6.35 (+0.07), ACHN: 13.06 (+1.22), SNSS: 2.48 (-0.03), ARRY: 4.64 (+0.07)
Cardiomyopathy - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/qz4fhf/cardiomyopathy) has announced the addition of the "Cardiomyopathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cardiomyopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cardiomyopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned - Array BioPharma Inc. - Torrent Pharmaceuticals Limited - LG Life Sciences, Ltd. - Genethon - Fibrotech Therapeutics Pty. Ltd. - Beech Tree Labs, Inc. For more information visit http://www.researchandmarkets.com/research/qz...iomyopathy
ARRY: 4.64 (+0.07)
Oncothyreon secures exclusive license to HER2 inhibitor
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 9:50AM CST
ONTY: 1.89 (+0.01), ARRY: 4.64 (+0.07)
Array BioPharma Advances To All Systems Go, Collects $85 Million
Clinically Sound Investor - at Seeking Alpha - Fri Dec 12, 8:13AM CST
ARRY: 4.64 (+0.07), EXEL: 1.29 (-0.01)
Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380
GlobeNewswire - Fri Dec 12, 6:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that Array BioPharma Inc. (Nasdaq:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380.
ONTY: 1.89 (+0.01), ARRY: 4.64 (+0.07)
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), INCY: 71.57 (+1.99), AMGN: 160.67 (+3.15), ARRY: 4.64 (+0.07)
Array BioPharma (ARRY) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:43AM CST
Array BioPharma (ARRY) Shares March Higher, Can It Continue?
ARRY: 4.64 (+0.07)
Array BioPharma, Inc. (ARRY) in Focus: Stock Soars 14.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:18AM CST
Array BioPharma, Inc. (ARRY) was a big mover last session, as the company saw its shares rise by over 14% on the day.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), AFFX: 9.80 (+0.05), ARRY: 4.64 (+0.07)
After Yesterday's Rally of 14.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Dec 04, 4:32PM CST
Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $4.38 to a high of $4.84. Yesterday, the shares gained 14.3%, which took the trading range above the 3-day high of $4.04 on volume of 17.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARRY: 4.64 (+0.07)
Why Array Biopharma Inc. Stock Roared Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 04, 2:59PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Array Biopharma , a clinical-stage...
GSK: 42.85 (+0.11), NVS: 93.91 (+0.66), ARRY: 4.64 (+0.07)
Array BioPharma Regains Binimetinib Rights from Novartis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:00PM CST
Shares of Array BioPharma Inc. (ARRY) shot up in after-market hours trading after the company announced reaching a definitive agreement with Novartis (NVS) to regain full worldwide rights to oncology candidate binimetinib, an MEK inhibitor.
BIIB: 340.89 (+5.13), GSK: 42.85 (+0.11), ARRY: 4.64 (+0.07), NVS: 93.91 (+0.66)
Array Biopharma Up 17.3%, Shares Break Through Resistance (ARRY)
Comtex SmarTrend(R) - Thu Dec 04, 10:06AM CST
Array Biopharma (NASDAQ:ARRY) is one of today's best performing low-priced stocks, up 17.3% to $4.59 on 7.9x average daily volume. Array Biopharma has traded 10.5 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has outperformed the Dow (17.3% to the Dow's -0.4%) and outperformed the S&P 500 (17.3% to the S&P's -0.5%) during today's trading.
ARRY: 4.64 (+0.07)
Array BioPharma (ARRY) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Dec 04, 7:55AM CST
ARRY: 4.64 (+0.07)
Array set for gap up at the open
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 6:37AM CST
ARRY: 4.64 (+0.07)
Array BioPharma to regain global rights to cancer therapy
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 5:33PM CST
GSK: 42.85 (+0.11), NVS: 93.91 (+0.66), ARRY: 4.64 (+0.07)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 4:39PM CST
TLYS: 9.47 (-0.03), HE: 33.35 (+0.17), WWWW: 19.23 (-0.03), PES: 5.60 (+0.13), ARO: 2.30 (-0.03), AVGO: 100.72 (-0.06), LDOS: 44.41 (+0.10), GST: 2.47 (-0.03), CSH: 22.16 (-0.46), ARRY: 4.64 (+0.07)
Array Biopharma Regains Rights to Cancer Drug From Novartis
at The Street - Wed Dec 03, 3:01PM CST
The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.
NVS: 93.91 (+0.66), ARRY: 4.64 (+0.07)
Array To Regain Worldwide Rights To Binimetinib
PR Newswire - Wed Dec 03, 3:01PM CST
Array BioPharma Inc. (NASDAQ: ARRY) today announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected in the first half of 2015, and remain subject to regulatory approval. Array had previously granted Novartis worldwide exclusive rights to develop and commercialize binimetinib under a 2010 License Agreement, which will terminate and be superseded by a new set of agreements between the parties.
ARRY: 4.64 (+0.07), NVS: 93.91 (+0.66)
Array BioPharma To Present At The Piper Jaffray And Oppenheimer 2014 Healthcare Conferences
PR Newswire - Tue Nov 25, 1:00PM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the following upcoming conferences. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: www.arraybiopharma.com.
ARRY: 4.64 (+0.07)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 3.02 (-0.05), CRIS: 1.29 (+0.04), IMMU: 4.41 (+0.13), PCYC: 121.84 (+1.15), ONCY: 0.49 (unch), PFE: 31.42 (-0.03), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), JNJ: 104.59 (+0.31), SNTA: 2.63 (+0.02), NVS: 93.91 (+0.66), XLRN: 38.80 (+0.80), ARRY: 4.64 (+0.07), CELGZ: 3.34 (-0.01), EXEL: 1.29 (-0.01)